Global Hepatology Society Statement

May 17, 2021

Vaccination for SARS-CoV-2 in Patients with Liver Disease

As global societies committed to helping patients with liver disease, we have been closely monitoring developments around the SARS-CoV-2 virus and its impact on those in our care. It is for that reason that we four societies have taken the following positions around the COVID-19 vaccination:

- We strongly recommend that all patients with liver disease (viral and non-viral disease, including fatty liver) undergo immunization with any authorized COVID-19 vaccine that is offered to them.

- We recommend that patients with advanced chronic liver disease, liver cancer, and those post-liver transplant should be prioritized for vaccination for SARS-CoV-2.

- Whilst the vaccine trials have not comprehensively evaluated safety in patients with chronic liver disease, there are no data to suggest that COVID-19 vaccines cause any adverse outcomes in this group of patients, including organ rejection or flares of autoimmune disease.

- Only by achieving global coverage can we succeed in our battle against SARS-CoV-2. We therefore encourage governments to ensure vaccines are distributed to low- and middle-income countries to provide equitable access.